The depression-dejection scale baseline score using POMS was not provided, but the change difference between pre- and posttreatment was reported. The change in depression-dejection score was lower than −1 in the treatment group and statistically significant when compared to the change in the control group.
Female (10 in the treatment group) Male (4 in the treatment group) No information provided on the number of female and male subjects in the control group
Patients with depression and/or anxiety
Patients scoring more than 7 in the Montgomery-Asberg Depression Rating Scale and/or the Tyrer Brief Anxiety Scale
The baseline using the Montgomery-Asberg Depression Rating Scale was 19.8 in the control group and 30 in the treatment group. The baseline using the HADS was 14.6 and 15.3 in the control and treatment group, respectively.
Individuals with cancer with a wide variety of levels of physical and psychological symptoms
Baseline score using HADS was not stated. Only the median change in HADS was provided being 0 for the aromatherapy group, −1.5 for the massage group, −0.5 for the aromatherapy massage group, and 0.5 for the control.
52.1; 52.8 for the usual care group; and 51.5 for the usual care plus aromatherapy group
Female (250), male (38)
Individuals with cancer
Patients diagnosed with cancer, a prognosis of more than 3 months, with clinical anxiety or depression
The baseline score using the Center for Epidemiological Studies Depression Scale was 26.1 for the aromatherapy group and 26 for the group receiving usual care (control).
52.5; 51.1 for the aromatherapy group; and 54 for the cognitive behavior therapy group
Female (31), male (8)
Individuals with cancer
Patients diagnosed for at least one month, who also had at least a predicted survival of 6 months and score 11 or more in the HADS for anxiety or depression
The baseline score in the depression-dejection subscale of POMS was 11.2 for the aromatherapy massage group and 13.4 for the control group.
53.70 for the control group (49.42–57.98), 52 (47.12–56.88) for the massage therapy group, and 53.35 (49.01–57.69)
Female (90)
Women who entered their menopausal period naturally
Woman, age between 45 and 60 years, with amenorrhea for at least 1 year
At baseline, according to the Menopause Rating Scale, the frequency of the severity of the depressive mood was reported as mild (14.9%), moderate (36.8%), severe (20.7%), and very severe (2.3%). No difference was found among the groups at baseline.
Women whose children were diagnosed with attention deficit hyperactivity disorder
Baseline using the Beck Depression Inventory was 8.6 in the control group and 10.8 in the treatment group.
In this study, both aromatherapy modalities were tested, inhalation aromatherapy and aromatherapy massage. Therefore, the study was included in both categories in the table. NA, not available; HADS, Hospital Anxiety and Depression Scale; POMS, Profile of Mood States.